Atara Biotherapeutics (ATRA) Non-Current Assets (2013 - 2026)

Atara Biotherapeutics has reported Non-Current Assets for 14 years, with the latest figure at $7.8 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets fell 77.55% year-over-year to $7.8 million; the trailing twelve-month figure through Mar 2026 stood at $39.7 million (down 78.51% YoY), and the FY2025 full-year result was $8.0 million, down 81.85% from the prior year.
• Non-Current Assets for Q1 2026 stood at $7.8 million, down from $8.0 million in the prior quarter.
• The five-year high for Non-Current Assets was $89.1 million in Q2 2022, with the low at $7.8 million in Q1 2026.
• Historically, Non-Current Assets has averaged $53.4 million across 5 years, with a median of $58.8 million in 2024.
• Annual changes were most pronounced in 2022 — Non-Current Assets jumped 38.27% — and 2025, when it tumbled 81.85%.
• Atara Biotherapeutics' Non-Current Assets stood at $81.3 million in 2022, then declined by 21.77% to $63.6 million in 2023, then tumbled by 30.54% to $44.2 million in 2024, then plunged by 81.85% to $8.0 million in 2025, then retreated by 2.48% to $7.8 million in 2026.
• The last three Non-Current Assets figures came in at $7.8 million (Q1 2026), $8.0 million (Q4 2025), and $11.7 million (Q3 2025), per Business Quant data.